Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CVN-293 by Cerevance for Amyotrophic Lateral Sclerosis: Likelihood of Approval
CVN-293 is under clinical development by Cerevance and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase...
Data Insights
CVN-293 by Cerevance for Alzheimer's Disease: Likelihood of Approval
CVN-293 is under clinical development by Cerevance and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase I...